Compass Therapeutics (CMPX) Equity Ratio (2023 - 2025)
Historic Equity Ratio for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to 0.91.
- Compass Therapeutics' Equity Ratio fell 231.77% to 0.91 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.91, marking a year-over-year decrease of 231.77%. This contributed to the annual value of 0.89 for FY2024, which is 579.83% down from last year.
- Compass Therapeutics' Equity Ratio amounted to 0.91 in Q3 2025, which was down 231.77% from 0.8 recorded in Q2 2025.
- In the past 5 years, Compass Therapeutics' Equity Ratio ranged from a high of 0.97 in Q1 2024 and a low of 0.8 during Q2 2025
- Moreover, its 3-year median value for Equity Ratio was 0.93 (2023), whereas its average is 0.91.
- As far as peak fluctuations go, Compass Therapeutics' Equity Ratio soared by 453.5% in 2024, and later crashed by 1493.26% in 2025.
- Compass Therapeutics' Equity Ratio (Quarter) stood at 0.95 in 2023, then decreased by 5.8% to 0.89 in 2024, then grew by 1.62% to 0.91 in 2025.
- Its last three reported values are 0.91 in Q3 2025, 0.8 for Q2 2025, and 0.84 during Q1 2025.